TG Therapeutics (NASDAQ:TGTX) Rating Increased to Strong-Buy at B. Riley

B. Riley upgraded shares of TG Therapeutics (NASDAQ:TGTX) to a strong-buy rating in a research note issued to investors on Tuesday,Zacks.com reports. B. Riley also issued estimates for TG Therapeutics’ Q1 2026 earnings at $0.45 EPS, Q2 2026 earnings at $0.49 EPS, Q3 2026 earnings at $0.46 EPS and Q4 2026 earnings at $0.52 EPS.

A number of other equities analysts have also recently weighed in on TGTX. Weiss Ratings reissued a “hold (c-)” rating on shares of TG Therapeutics in a research note on Wednesday, October 8th. JPMorgan Chase & Co. lifted their target price on shares of TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research report on Monday. The Goldman Sachs Group upgraded shares of TG Therapeutics to a “hold” rating and set a $37.00 price target for the company in a research report on Thursday, July 10th. Finally, HC Wainwright started coverage on shares of TG Therapeutics in a research note on Monday, October 6th. They issued a “buy” rating and a $60.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $50.25.

TG Therapeutics Price Performance

NASDAQ TGTX opened at $33.81 on Tuesday. TG Therapeutics has a 12 month low of $23.60 and a 12 month high of $46.48. The firm has a market capitalization of $5.36 billion, a PE ratio of 91.38 and a beta of 1.97. The company’s 50 day simple moving average is $33.66 and its 200 day simple moving average is $34.75. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $2.19. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The company had revenue of $161.71 million for the quarter, compared to analysts’ expectations of $152.12 million. During the same period last year, the firm earned $0.02 EPS. The firm’s revenue for the quarter was up 92.7% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that TG Therapeutics will post 0.08 EPS for the current fiscal year.

Insider Activity

In related news, Director Sagar Lonial sold 20,852 shares of the firm’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the sale, the director directly owned 94,061 shares in the company, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.64% of the stock is owned by company insiders.

Institutional Investors Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TGTX. State Street Corp boosted its stake in shares of TG Therapeutics by 2.5% during the 2nd quarter. State Street Corp now owns 7,618,238 shares of the biopharmaceutical company’s stock valued at $274,180,000 after buying an additional 184,339 shares during the period. Geode Capital Management LLC raised its holdings in shares of TG Therapeutics by 6.3% during the second quarter. Geode Capital Management LLC now owns 3,490,457 shares of the biopharmaceutical company’s stock worth $126,033,000 after acquiring an additional 207,890 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of TG Therapeutics by 21.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock worth $75,683,000 after acquiring an additional 345,059 shares in the last quarter. Hood River Capital Management LLC boosted its position in TG Therapeutics by 0.7% during the second quarter. Hood River Capital Management LLC now owns 1,567,506 shares of the biopharmaceutical company’s stock valued at $56,415,000 after purchasing an additional 11,018 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in TG Therapeutics by 1,809.9% during the first quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company’s stock valued at $47,830,000 after buying an additional 1,149,526 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.